These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 12389069

  • 1. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P, Nguyen L, Tranchand B, Puozzo C.
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [Abstract] [Full Text] [Related]

  • 2. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V, Puozzo C.
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [Abstract] [Full Text] [Related]

  • 3. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
    Gauvin A, Pinguet F, Culine S, Astre C, Gomeni R, Bressolle F.
    Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
    Bourgeois H, Vermorken J, Dark G, Jones A, Fumoleau P, Stupp R, Tourani J, Brain E, Nguyen L, Lefresne F, Puozzo C.
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
    [Abstract] [Full Text] [Related]

  • 5. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
    Puozzo C, Gridelli C.
    Clin Lung Cancer; 2004 Jan; 5(4):237-42. PubMed ID: 14967076
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
    Deporte-Fety R, Simon N, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Urien S.
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
    [Abstract] [Full Text] [Related]

  • 7. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 8. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
    Kitzen JJ, Puozzo C, de Jonge MJ, Brandely M, Verweij J.
    Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
    Rezai K, Urien S, Isambert N, Roche H, Dieras V, Berille J, Bonneterre J, Brain E, Lokiec F.
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
    [Abstract] [Full Text] [Related]

  • 10. Dexamethasone as a probe for vinorelbine clearance.
    Puisset F, Dalenc F, Chatelut E, Cresteil T, Lochon I, Tisnes P, Roché H.
    Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
    [Abstract] [Full Text] [Related]

  • 11. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
    Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C.
    Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS.
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [Abstract] [Full Text] [Related]

  • 13. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
    Lush RM, McCune JS, Tetteh L, Thompson JA, Mahany JJ, Garland L, Suttle AB, Sullivan DM.
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
    [Abstract] [Full Text] [Related]

  • 14. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, Leopold LH.
    Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
    [Abstract] [Full Text] [Related]

  • 15. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T.
    Clin Cancer Res; 2006 Jan 15; 12(2):516-22. PubMed ID: 16428494
    [Abstract] [Full Text] [Related]

  • 16. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H.
    J Clin Oncol; 2006 Jun 01; 24(16):2448-55. PubMed ID: 16651648
    [Abstract] [Full Text] [Related]

  • 17. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
    Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E.
    Paediatr Anaesth; 2005 Apr 01; 15(4):282-92. PubMed ID: 15787918
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
    Urien S, Brain E, Bugat R, Pivot X, Lochon I, Van ML, Vauzelle F, Lokiec F.
    Cancer Chemother Pharmacol; 2005 Jan 01; 55(1):55-60. PubMed ID: 15258698
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.
    Nguyen L, Tranchand B, Puozzo C, Variol P.
    Br J Clin Pharmacol; 2002 May 01; 53(5):459-68. PubMed ID: 11994051
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE, Chaudhary A, Ghosh A, Johnson RD.
    Cancer Chemother Pharmacol; 2006 Apr 01; 57(4):401-11. PubMed ID: 16322991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.